U.S. regulators have again approved a Merck & Co. tablet for gradually reducing seasonal allergies, this time for ragweed pollen.
Merck & Co. says the Food and Drug Administration has approved its new tablet for grass allergies, Grastek, for patients five to 65 years old.
(HealthDay)—Merck will pay $100 million to settle thousands of lawsuits over the company's NuvaRing birth control device, according to insiders.
Merck & Co. reported a 14 percent decline in fourth-quarter profit as generic competition continued to cut into sales of one-time blockbuster medicines, and unfavorable currency exchange rates reduced overseas revenue.
Merck & Co. says it's won its first approval for its new immunotherapy tablet for grass allergies, from regulators in Canada.
(HealthDay)—There may be good news coming in the form of a pill for the millions of Americans who suffer from ragweed allergy.
(HealthDay)—Packaging defects have prompted a recall of a combination cholesterol drug called Liptruzet, produced by Merck & Co., temporarily affecting the entire U.S. stock.
Forest Laboratories says it plans to cut $500 million in costs in about two years, and also plans to buy back up to $1 billion in company stock.
German chemicals and pharmaceuticals giant Merck KGaA said Thursday it is raising its full-year operating profit forecast thanks to improving sales and positive cost-cutting effects.
Merck & Co. said Monday that its third-quarter profit plunged 35 percent because of competition from generic drugs, lower sales of its top-selling medicine, and restructuring and acquisition charges. It still beat Wall Street's ...
Northwestern Medicine, Walgreens, Alliance of Chicago community health centers and Merck are collaborating on a study with a deceptively simple goal: provide clear instructions on prescription medicine labels so patients ...
Merck & Co. plans to cut another 8,500 jobs as the drugmaker continues its struggle with competition from cheaper generic medications that have squeezed the pharmaceutical industry for several quarters now.
German drug and high-tech materials company Merck KGaA bounced back from losses this time last year to record a net profit of 316 million euros ($420 million) in the second quarter.
Drugmaker Merck & Co.'s second-quarter profit fell by half as generic competition slashed revenue from several older medicines and sales of its top drug barely budged.
(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.